Menopausal hormone therapy after breast cancer: a meta-analysis and critical appraisal of the evidence
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Introduction: Menopausal hormone therapy (HT) is typically withheld from breast cancer survivors because of concerns about risk for recurrence. Our objectives were to estimate the effects of HT on recurrence in breast cancer survivors and to examine the reliability of these estimates. Methods: In a systematic review of the literature we identified all reports of HT use in breast cancer survivors that included comparison groups. Study design features that might affect selection of participants, detection of recurrence, and manuscript publication were assessed. The relative risks for breast cancer recurrence associated with HT were combined with random effects models. Results: Two randomized and eight observational studies included 1,316 breast cancer survivors who used HT and 2,839 nonusers. In the observational studies, HT users were younger and more commonly node negative; only two reported balanced restaging for HT and control groups. Randomized trials suggest that HT increased the risk for recurrence (relative risk 3.41, 95% confidence interval 1.59–7.33), whereas observational studies suggest that HT decreased this risk (relative risk 0.64, 95% confidence interval 0.50–0.82). Conclusion: Results from observational studies of HT conducted in breast cancer survivors are discrepant with results from randomized trials. Observational studies of HT use in breast cancer survivors have design limitations that cannot be controlled for using standard statistical methods. Therefore, the randomized clinical trial data provide the only reliable estimates of the effect of HT use on recurrence risks in breast cancer survivors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cauley, J. A., Lucas, F. L., Kuller, L. H., Stone, K., Browner, W., Cummings, S. R., & for the Study of Osteoporotic Fractures Research Group (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-4_part_1-199902160-00004 · Cited by 409
Cited by
The 2017 hormone therapy position statement of The North American Menopause Society
(2017) · Menopause · doi:10.1097/gme.0000000000000921 · Cited by 1,001
The 2022 hormone therapy position statement of The North American Menopause Society
(2022) · Menopause · doi:10.1097/gme.0000000000002028 · Cited by 977
The 2012 Hormone Therapy Position Statement of The North American Menopause Society
(2012) · Menopause · doi:10.1097/gme.0b013e31824b970a · Cited by 785
Postmenopausal Hormone Therapy: An Endocrine Society Scientific Statement
Santen, R. J., Allred, D. C., Ardoin, S. P., Archer, D. F., Boyd, N., Braunstein, G. D., Burger, H. G., Colditz, G. A., Davis, S. R., Gambacciani, M., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2509 · Cited by 680
(2013) · Menopause · doi:10.1097/gme.0b013e3182a122c2 · Cited by 560
Increased Risk of Recurrence After Hormone Replacement Therapy in Breast Cancer Survivors
Holmberg, L., Iversen, O.-E., Rudenstam, C. M., Hammar, M., Kumpulainen, E., Jaskiewicz, J., Jassem, J., Dobaczewska, D., Fjosne, H. E., Peralta, O., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn058 · Cited by 344
Golder, S., Loke, Y. K., & Bland, M. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1001026 · Cited by 269
Anderson, D. J., Seib, C., McCarthy, A. L., Yates, P., Porter-Steele, J., McGuire, A., & Young, L. (2015) · Menopause · doi:10.1097/gme.0000000000000421 · Cited by 45
Hormone replacement therapy and women with premature menopause–a cancer survivorship issue
King, J., Wynne, C. H., Assersohn, L., & Jones, A. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.04.007 · Cited by 34
Metadata
- Authors
- Col, N. F., Kim, J. A., & Chlebowski, R. T.
- Venue
- Breast Cancer Research
- Published
- 2005-05-19
- Volume
- 7
- Issue
- 4
- Pages
- R535-40
- ISSN
- 1465-5411 (ISSN-L)
- 1465-542X
- OpenAlex
- W2135265943
- Cited by
- 105
- References
- 1
- FWCI
- 0.68
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.